跳至主要内容
临床试验/ITMCTR2100004943
ITMCTR2100004943招募中1 期

A multicentre, randomized, single-blind, parallel-controlled study of acupoint catgut embedding for metabolic fatty liver disease

Shuguang Hospital affiliated to Shanghai Universtiy of Traditonal Chinese Medicine0 个研究点开始时间: 待定最近更新:

试验速览

阶段
1 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

性别
All

入选标准

  • 1. Meet MAFLD diagnostic criteria;
  • 2. ALT and AST are 5 times lower than the upper limit of normal;
  • 3. Between the ages of 18 and 65 years old, regardless of gender;
  • 4. Not taking drugs related to THE treatment of MAFLD;
  • 5. Signed informed consent.
  • 5) Signing the informed consent.

排除标准

  • 1. Other acute or chronic liver diseases;
  • 2. Patients with serious primary diseases such as heart, brain, kidney and hematopoietic system;
  • 3. Patients with acute fatty liver of pregnancy, lipid deposition disease, focal fatty liver, hepatic adipose tumor, etc.;
  • 4. Psychopaths;
  • 5. Women who are pregnant or trying to become pregnant, breast-feeding women;
  • 6. Unstable body weight (change > 5% in the first 3 months);
  • 7. Patients with diabetes who are taking insulin or oral hypoglycemic drugs;
  • 8. Current use of weight loss medications (e.g. Orlistat);
  • 9. Patients with anaphylactic specific constitution;
  • 10. Those who cannot strictly follow the treatment plan.

研究者

发起方
Shuguang Hospital affiliated to Shanghai Universtiy of Traditonal Chinese Medicine

相似试验